Target Audience
This activity has been designed to meet the educational needs of hematologists, physicians, physician assistants, nurse practitioners, registered nurses, physical therapists, social workers, and other specialists of the hemophilia treatment center (HTC) team, as well as clinicians interested in the treatment and management of patients with hemophilia.

Statement of Need/Program Overview
Providing the best care possible to patients with hemophilia requires staying up-to-date on new and ongoing research and clinical trials. This educational activity is designed to present newly released clinical data on hemophilia, from scientific posters, abstracts, and published articles, to clinicians who are unable to attend medical congresses throughout the year. Providing hemophilia treatment center clinicians with this latest information from experts in the field enables them to continue to optimally address clinical challenges to hemophilia management in their everyday practice.

Educational Objectives
After completing this activity, the participant should be better able to:

• Discuss new clinical data from scientific posters, abstracts, and published articles about hemophilia and their bearing on clinical practice
• Assess evidence and expert commentary regarding diagnosis, treatment, and management of hemophilia with inhibitors
• Differentiate between therapeutic options for patients with severe hemophilia who have or are at risk for developing inhibitors
• Integrate expert recommendations concerning a case study into patient management strategies
• Provide appropriate care and counsel for patients and their families

Miguel A. Escobar, MD
Department of Pediatrics and Internal Medicine
Division of Hematology
Associate Professor, The University of Texas Health Science Center at Houston
Associate Professor, The University of Texas MD Anderson Cancer Center
Medical Director, Gulf States Hemophilia and Thrombophilia Center
The University of Texas-Houston Medical School
Houston, Texas

Patrick F. Fogarty, MD
Director, Penn Comprehensive Hemophilia and Thrombosis Program
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Mark T. Reding, MD
Associate Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Brenda Riske, RN, MS, MBA, MPA
Director of Operations, Clinical Services & Research
University of Colorado School of Medicine
Center for Bleeding and Clotting Disorders
Aurora, Colorado

Tammuella Chrisentery Singleton, MD
Marcelle Schaefer Vergara Chair in Pediatric Hematology/Oncology
Assistant Professor of Pediatrics
Tulane University School of Medicine
Louisiana Center for Bleeding and Clotting Disorders
Tulane Hospital for Children
New Orleans, Louisiana

Leonard A. Valentino, MD
Professor
Rush University Medical Center
Chicago, Illinois

Miguel A. Escobar, MD
Department of Pediatrics and Internal Medicine
Division of Hematology
Associate Professor, The University of Texas Health Science Center at Houston
Associate Professor, The University of Texas MD Anderson Cancer Center
Medical Director, Gulf States Hemophilia and Thrombophilia Center
The University of Texas-Houston Medical School
Houston, Texas

Patrick F. Fogarty, MD
Director, Penn Comprehensive Hemophilia and Thrombosis Program
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Mark T. Reding, MD
Associate Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Tammuella Chrisentery Singleton, MD
Marcelle Schaefer Vergara Chair in Pediatric Hematology/Oncology
Assistant Professor of Pediatrics
Tulane University School of Medicine
Louisiana Center for Bleeding and Clotting Disorders
Tulane Hospital for Children
New Orleans, Louisiana

Leonard A. Valentino, MD
Professor
Rush University Medical Center
Chicago, Illinois

Program Agenda
40-minute live Webcast presentation;
20-minute interactive question-and-answer session


Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health (CMH) Foundation, and Educational Concepts in Medicine (ECM). The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 3 weeks (if applicable).

Fee Information
There is no fee for this educational activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty Presenter and Planning Committee	Reported Financial Relationship
Miguel A. Escobar, MD	Consulting Fees: Baxter Healthcare Corporation, Biogen Idec, GTC Biotherapeutics, Novo Nordisk Inc., Pfizer Inc.; Fees for Non-CME/CE Services Received Directly From a Commercial Interest or Their Agents: Novo Nordisk Inc.
Patrick F. Fogarty, MD	Consulting Fees: Amgen Inc., Baxter Healthcare Corporation, Biogen Idec; Contracted Research: Baxter Healthcare Corporation, Biogen Idec, CSL Behring
Mark T. Reding, MD	Consulting Fees: Baxter Healthcare Corporation, Bayer HealthCare, Biogen Idec, Novo Nordisk Inc., Octapharma, Pfizer Inc.
Brenda Riske, RN, MS, MBA, MPA	Consulting Fees: Bayer HealthCare
Tammuella Chrisentery Singleton, MD	Consulting Fees: Baxter Healthcare Corporation, CSL Behring, Pfizer Inc.; Fees for Non-CME/CE Services Received Directly From a Commercial Interest or Their Agents: Bayer HealthCare, Novo Nordisk Inc., Pfizer Inc.
Leonard A. Valentino, MD	Consulting Fees: Baxter Healthcare Corporation, Bayer HealthCare, Biogen Idec, GTC Biotherapeutics, Inspiration Biopharmaceuticals, Novo Nordisk Inc.

Name of Planner or Manager	Reported Financial Relationship
PIM Clinical Reviewers: Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN	Have no real or apparent conflicts of interest to report.
ECM: Patrick J. Crowley, MBA, Managing Director; Jodi Andrews, BS, Director, Educational Programs; Cory Lewis, Program Manager; Gay Boyle, MA, Editorial Services	Have no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Cardiovascular & Metabolic Health Foundation (CMH), Educational Concepts in Medicine (ECM), and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CMH, ECM, and Novo Nordisk Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Blood CME Center staff prior to the live event at (888) 525-1775.

Fee Information
There is no fee for this educational activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 3 weeks (if applicable).